Crouse Health Online: Wellness is just a click away.
Share Share
  |  Connect with Us: 
Text Size

Health News

Vaccine Studied for Deadly Brain Cancer

Vaccine Studied for Deadly Brain Cancer


TUESDAY, Oct. 5 (HealthDay News) -- Adding a new vaccine to standard therapy extended survival for people with the most deadly type of brain cancer in a small study.

Researchers from Duke University Medical Center and the University of Texas M.D. Anderson Cancer Center report that the case-control study included 35 patients newly diagnosed with the brain cancer, known as glioblastoma (GBM). The patients were divided into two groups: Both received surgery, radiation and the chemotherapy drug temozolomide, but one group of 18 patients also began receiving injections of the new vaccine one month after completing radiation and continued to receive the vaccine as long as it appeared to be effective.

Median survival time for those in the vaccine group was 26 months, compared with 15 months for the control group. Progression-free survival was 14.2 months in the vaccine group, compared to 6.3 months in the control group.

The vaccine appeared to stimulate an immune response in approximately half of the patients who received it, suggesting such responses were linked to increased survival time, "but the numbers are so small that we cannot conclude this with any degree of certainty," Dr. Amy Heimberger, co-lead investigator from M.D. Anderson, said in a news release from Duke.

The vaccine knocks out a growth factor associated with the most aggressive form of the brain cancer.

"About a third of all glioblastomas are fueled by a very aggressive cancer gene, called EGFRvIII; these tumors are the 'worst of the worst,'" Dr. John Sampson, a professor of neurosurgery at Duke University Medical Center, said in the news release.

The presence of EGFRvIII allows cancer cells to multiply out of control, seeding new tumors throughout the brain, the researchers explained. Even with advances in chemotherapy and radiation, prognosis for patients with glioblastoma is poor, with an average survival time of one year after diagnosis.

About 10,000 new cases of glioblastoma appear in the United States every year.

"Our study showed that the vaccine eliminated all of the cancer cells carrying this marker in all but one of our study participants," study senior author Dr. Darell D. Bigner, director of the Preston Robert Tisch Brain Tumor Center, said in the news release. (Bigner is one of three scientists who discovered the gene variant EGFRvIII.)

The vaccine is known variously as CDX-110 by Celldex Therapeutics or PF-04948568 by Pfizer.

The study appears online Oct.4 in the Journal of Clinical Oncology.

Drs. Bigner, Heimberger and Sampson, along with Duke University and M.D. Anderson, have potential conflicts of interest from consulting agreements, stock options and possible licensing fees, according to background material for the study. Duke and M.D. Anderson have plans in place to manage potential conflict of interest, the statement said.

More information

The U.S. National Cancer Institute has more about brain tumors.

Copyright © 2010 HealthDay. All rights reserved.

Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.


Latest News

Crouse Hospital Appoints Chief Information Officer
more >

MedEx Bedside Prescription Delivery Service

Free service offers convenience, patient education at discharge.
more >

CrouseSports Express After-Hours Ortho Care

Immediate care of orthopedic injuries in kids and adults.
more >

Weight Loss Surgery

Is it right for you? Attend a free information seminar held twice monthly.
more >

Quality at Crouse

See how Crouse Hospital strives to provide the best in patient care.
more >

Cheer Up That Special Someone

Say get well or welcome a new arrival with a gift purchased right at Crouse.

more >

Make an Online Donation Now

Your donation of any amount helps support Crouse services & programs in a meaningful way.
more >

Shop Online Now

Say get well, thinking of you or welcome new baby with a unique gift from the Crouse Gift Shop.

more >